Objectives: To determine the prevalence of depressive symptoms among oncology patients and identify simultaneous use of antineoplastic and antidepressant agents. Methods: This was a cross-sectional study that interviewed 56 oncology patients using two data collection instruments: a questionnaire covering clinical and sociodemographic data and the Beck Depression Inventory-II (BDI-II), for assessment of depressive symptoms. For data analysis, descriptive statistics were used to determine the prevalence of depressive symptoms and the chi-square test was used to evaluate associations between sociodemographic and clinical variables and depressive symptoms. Results: A 26.7% (15 patients) prevalence of depression was detected. Just eight of these 15 patients (53.3%) were receiving treatment for depression. In the sample as a whole, 13 of the patients interviewed (23.2%) were taking antidepressants and 11 of these 13 patients (19.6%) were taking antidepressive and antineoplastic agents simultaneously. A total of five (8.9% of the sample) contraindicated drug interactions were detected. Conclusions: Depressive symptoms are more prevalent among cancer patients than in the general population, but they are generally under-diagnosed and under-treated. Simultaneous use of antidepressant and antineoplastic agents is common and so, in order to reduce the number of harmful adverse effects, possible drug interactions must be identified before antidepressants are prescribed to cancer patients. Keywords: Antidepressive agents, antineoplastic agents, drug interactions, depression, neoplasms.
Introduction
The physiological and emotional changes that patients with cancer go through very often cause psychological suffering and predispose them to psychiatric disorders or exacerbate pre-existing psychiatric conditions. It is already known that psychiatric disorders are more prevalent among oncology patients than in the general population, affecting around 30-40% of patients with cancer. 1 The prevalence of depressive symptoms among oncology patients varies depending on type of cancer, disease stage, moment and method of symptom assessment, diagnostic criteria applied and the demographic profile of the population studied. 2 Prevalence rates of depressive symptoms vary from approximately 10 to around 40% of patients with cancer. 3 Prevalence rates are even greater among patients who are taking antineoplastic medications such as interferon-alpha, which is a treatment that is associated with depression in 21 to 58% of cases. 4 Psychotropic drugs are often prescribed for patients with cancer, both for treatment of symptoms such as insomnia, pain or nausea and also to treat psychiatric disorders. One study conducted in North America assessing prescription of antidepressants to patients with cancer observed that such drugs are prescribed to one in every seven patients treated in outpatients or clinics. 3 Many antineoplastic drugs share the same metabolic pathways as psychotropic agents; for example those that undergo transformation by CYP 450 3A4. Coadministration of these antineoplastic agents with antidepressive agents such as fluoxetine, sertraline, paroxetine and fluvoxamine, which are inhibitors of this cytochrome isoform, can reduce the efficacy of the antineoplastic or increase its toxicity. 5 Additionally, pharmacodynamic interactions can result from synergism or antagonism of the physiological effects of drugs. and their better safety profiles in oncology patients. 5 Additionally, it is also of interest to consider whether some of the side effects of these medications may be beneficial to the patient, such as the analgesic and antiemetic effects often observed with mirtazapine. 7 Patients who take psychotropic and antineoplastic agents concomitantly are exposed to the risk of drug 
Method Sample
A cross-sectional study was conducted of 56 oncology patients seen at the Oncology Clinic at HSL-PUCRS. Over a 3-week period, from January to February of 2014, patients seen at the clinic were invited to take part in the study, forming a sample of convenience.
Ethical considerations
All patients who agreed to take part and signed the free and informed consent form were enrolled on the study. Patients were excluded if they were incapable of reading or understanding the data collection instruments 
Instruments
The research instrument employed for data collection was the Beck Depression Inventory-II (BDI-II).
been treated by a psychiatrist. The majority of patients'
perceived their own health to be good (58.9%) ( Table 2 ).
The prevalence of a positive BDI-II screening result for moderate to severe depressive symptoms among the sample of patients who took part in this study was 26.7% (15 cases). The mean BDI score was 14.7 points and the highest score was 55 points.
Analysis of adjusted residuals showed that patients who considered their own health to be poor or very poor had a stronger association with positive BDI-II screening results (p = 0.009) ( Table 3 ).
Patients who reported that their marital status was widowed had a stronger association with positive BDI-II screening results (p = 0.035). There were no correlations between depressive symptoms and sex, age or any other clinical or sociodemographic findings ( 
Statistics
The prevalence of depressive symptoms was determined and the sample was characterized using descriptive statistics. The chi-square test was used to assess risk factors associated with depressive symptoms, considering results with a p value less than 0.05 to be significant. Analyses were conducted using SPSS, version 17.0.
Results
A total of 14 men and 42 women were interviewed.
Patients were aged from 27 to 78 years, with a mean of 56.5 years. This study also detected a significant association between depressive symptoms and patients who were widows, which is similar to a study of breast cancer patients that found that divorced and widowed women exhibited higher rates of obsessive and depressive findings, and it is easy to imagine that these life-changing events are associated with greater vulnerability and with failures of these patients' support networks, 19 since social support can ameliorate reactions to stressful events. The sociodemographic questionnaire administered in the present study detected 13 patients (23.2%) who were taking antidepressants, which is a similar pattern to that found by a study conducted at a community cancer treatment center, where 16% of patients were taking antidepressive medication. 21 It is important to remember that antidepressant agents are also prescribed to treat other medical conditions, such as the symptoms of menopause and pain. 21 The fact that patients were taking antidepressant drugs was only recorded on the medical records for three (23%) of the 13 patients who reported that they were taking them during the interview conducted to administer the sociodemographic questionnaire. The fact that this information was missing supports the hypotheses that these patients may not be mentioning information related to psychiatric disorders during their consultations or that treating physicians may not be recognizing that the severity of depressive symptoms is sufficient to warrant a need for antidepressant medication. 21 Oncologists have an increased tendency to underestimate depressive symptoms in more severe patients and screening could prove more effective if cognitive symptoms such as anhedonia, suicidal ideation and despair were recognized. 24 This study also detected a high number of possible drug interactions, since five (45.5%) of the 11 patients who were simultaneously taking antidepressant and antineoplastic agents were taking drugs which, according to a review conducted by the authors of the study, are contraindicated because of interactions. This rate is 2.5 times the number of potential drug interactions (whether clinical or theoretical) detected in a study conducted in Singapore. 6 Drug interactions can result in reduced drug efficacy and increased adverse effects.
Limitations of this study include the small sample size and the fact that only one instrument was used to screen for depressive symptoms, with no diagnostic confirmation. Notwithstanding, this instrument has been validated for the Brazilian population and has been widely employed to screen for depression in many different studies. 25, 26 Among cancer patients, depression causes increased suffering, lower quality of life and reduced commitment to treatment and can increase the number of days spent in hospital. 5, 27 It has been observed that mortality rates among cancer patients increase by up to 25% when they have depressive symptoms, 13, 22 possibly due to changes to neuro-immuno-endocrine factors. 27 Despite the significance of data on related morbidity and mortality, few studies have evaluated depressive symptoms in cancer patients in Brazil, highlighting the need to conduct studies with larger samples that could confirm the findings reported above.
Along same lines, it could be helpful to develop protocols providing guidance for clinical conduct of the treatment of depressive episodes in oncology patients, which would be of help to both oncologists and psychiatrists.
Conclusions
There is a high prevalence of depressive symptoms among cancer patients. Utilization of simple, rapidlyadministered screening instruments such as the BDI-II is important for identification of depressive symptoms in oncological contexts. This study found that just half of the patients whose screening results were positive for depressive symptoms were receiving antidepressant treatment, highlighting the importance of this diagnostic practice.
Furthermore, a large percentage of patients were simultaneously taking medications with a high potential for interaction. This underscores the need to increase the attention that is paid to choosing an antidepressant agent for patients who are taking antineoplastic agents, in order to avoid potential side effects or reductions in the efficacy of both treatments.
